Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in Non‐Muscle Invasive Bladder CancerTakahisa Yamashita(Saitama Medical University), Shuji Momose(Social Insurance Saitama Chuo Hospital)Pathology InternationalFebruary 12, 202510.1111/pin.70002Cited by 2SaveCiteExport RISWatch citationsRelated PapersLUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells|Blood|2020|54Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer|International Journal of Oncology|2017|30